Table 2.
Baseline medications
| Medication | BMS‐986231 treatment dosage | ||||
|---|---|---|---|---|---|
|
Placebo group
(n = 12) |
3 µg/kg/min (n = 6) | 5 µg/kg/min (n = 9) | 7 µg/kg/min (n = 12) | 12 µg/kg/min (n = 7) | |
| Renin–angiotensin system blockers, n (%) | 9 (75.0%) | 3 (50.0%) | 9 (100%) | 11 (91.7%) | 6 (85.7%) |
| Beta‐blockers, n (%) | 12 (100%) | 4 (66.7%) | 8 (88.9%) | 12 (100%) | 7 (100%) |
| Calcium channel blockers, n (%) | 1 (8.3%) | 0 | 0 | 1 (8.3%) | 1 (14.3%) |
| Cardiac therapy, n (%) | 9 (75.0%) | 6 (100%) | 7 (77.8%) | 9 (75.0%) | 3 (42.9%) |
| Amiodarone | 3 (25.0%) | 1 (16.7%) | 3 (33.3%) | 3 (25.0%) | 1 (14.3%) |
| Digoxin | 4 (33.3%) | 2 (33.3%) | 2 (22.2%) | 3 (25.0%) | 0 |
| Dobutamine | 0 | 1 (16.7%) | 1 (11.1%) | 0 | 0 |
| Glyceryl trinitrate | 0 | 2 (33.3%) | 1 (11.1%) | 1 (8.3%) | 0 |
| Isosorbide dinitrate | 5 (41.7%) | 2 (33.3%) | 1 (11.1%) | 3 (25.0%) | 0 |
| Isosorbide dinitrate/hydralazine | 0 | 0 | 1 (11.1%) | 0 | 0 |
| Isosorbide mononitrate | 0 | 1 (16.7%) | 1 (11.1%) | 2 (16.7%) | 0 |
| Ivabradine | 0 | 0 | 0 | 1 (8.3%) | 1 (14.3%) |
| Milrinone | 0 | 0 | 0 | 0 | 1 (14.3%) |
| Diuretics, n (%) | 11 (91.7%) | 6 (100%) | 9 (100%) | 12 (100%) | 7 (100%) |
| Antithrombotic agents, n (%) | 11 (91.7%) | 6 (100%) | 8 (88.9%) | 11 (91.7%) | 6 (85.7%) |
| Lipid‐modifying agents, n (%) | 9 (75.0%) | 4 (66.7%) | 4 (44.4%) | 6 (50.0%) | 1 (14.3%) |
| Other antihypertensives, n (%) | 3 (25.0%) | 3 (50.0%) | 2 (22.2%) | 4 (33.3%) | 1 (14.3%) |